Autosomal Dominant Intellectual Disability-Craniofacial Anomalies-Cardiac Defects Syndrome

Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome is a lifelong condition that affects brain development, facial shape, growth, and several organs—especially the heart and gastrointestinal system. Most people have developmental delay and intellectual disability (how much this affects learning varies), speech and feeding difficulties in infancy, distinctive facial features, and a higher chance of congenital heart defects such as holes between the heart chambers. Eye movement problems (like strabismus), reflux or constipation, sleep problems, and frequent infections are also reported. The condition happens because one working copy of the KAT6A gene is disrupted, which alters how DNA is packaged and “read” in cells (histone acetylation), changing many downstream developmental programs. PMC+3National Organization for Rare Disorders+3Wikipedia+3

Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome is a rare genetic condition in which a single changed copy of a gene is enough to cause problems with learning and development. Many children have developmental delay, speech delay, distinct facial features, and congenital heart defects such as holes between the heart chambers. Doctors often link this syndrome to pathogenic variants in the KAT6A gene, and the disorder is also known as Arboleda-Tham (KAT6A) syndrome. Because it is autosomal dominant, the variant can be inherited from an affected parent or happen for the first time in a child (de novo). Ma’ayan Lab+3rarediseases.info.nih.gov+3orpha.net+3

This syndrome usually starts to show at birth or in infancy. Typical findings include low muscle tone (hypotonia), feeding difficulty, small head size in some children, and eye problems such as strabismus; about half of patients have a heart problem like atrial or ventricular septal defects or patent ductus arteriosus. The pattern varies from child to child, so care is individualized. orpha.net+1

Types

There is not a formal “subtype A/B/C,” but specialists often talk about types in three practical ways that help with prognosis and care:

1) By genetic variant class. Many individuals have truncating variants (nonsense, frameshift, some splice variants) that cut the protein short; others have missense variants that swap one amino acid for another. Truncating variants—especially those toward the end of the gene (“late-truncating”)—have been linked with more severe feeding and speech challenges in cohort studies. Missense variants are less common and sometimes inherited. Zebrakinder+2PubMed+2

2) By origin of the variant. Most cases are de novo (new changes not present in either parent). Rarely, an affected parent passes the variant to a child, consistent with autosomal dominant inheritance (each child would have a 50% chance). Germline mosaicism in an apparently unaffected parent is also possible but uncommon. PubMed+1

3) By clinical severity. Clinicians sometimes describe milder vs more pronounced presentations based on language development, feeding support needs, congenital heart disease, and additional neurological features (such as seizures), guided by published cohorts and natural-history reviews. PubMed+1

Causes

In this context, “causes” means genetic and biological mechanisms known to produce the syndrome (not parenting, nutrition, or environment). Each item describes a mechanism that has been reported or reasoned from cohort and molecular studies of KAT6A.

1. Pathogenic truncating variants in KAT6A (nonsense/frameshift) that stop the protein early, disturbing its acetyltransferase function and chromatin regulation. PMC

2. Late-truncating variants associated with more severe feeding/speech issues in group analyses. Zebrakinder

3. Missense variants that alter critical domains (e.g., HAT or PHD domains), changing enzyme activity or protein interactions. Zebrakinder

4. Splice-site variants that misprocess RNA, leading to abnormal or truncated protein. PubMed

5. De novo variants arising in the egg or sperm or early embryo (most cases). PubMed

6. Dominant inheritance from an affected parent (uncommon but reported). ScienceDirect

7. Germline mosaicism in a parent (rare, explains recurrence with unaffected parents). PubMed

8. Loss of KAT6A histone acetylation activity (reduced H3K9/H3K18 acetylation), altering gene expression programs during development. HERO

9. Perturbed p53 signaling downstream of KAT6A dysfunction, affecting cell cycle and differentiation. HERO

10. Haploinsufficiency—one functional copy of KAT6A is not enough for normal development. PMC

11. Gene-disrupting structural changes (e.g., rare intragenic deletions/insertions that inactivate KAT6A). (General mechanism inferred for single-gene dominant disorders and reflected across KAT6A variant catalogs.) PubMed

12. Pathogenic variants affecting the HAT domain (the catalytic core), especially harmful due to direct loss of acetyltransferase activity. Zebrakinder

13. Variants impacting protein interaction domains (e.g., PHD fingers), mis-coordinating chromatin complexes. Zebrakinder

14. Regulatory variants near KAT6A (rare; theoretically reduce gene expression), functionally similar to loss-of-function. (Supported by the principle of haploinsufficiency in KAT6A cohorts.) PubMed

15. Mosaic KAT6A variants in the child, producing mixed cell populations and variable features. (Reported in the broader chromatin-disorder literature; occasionally seen in dominant neurodevelopmental syndromes.) PubMed

16. De novo post-zygotic variants during early embryogenesis, explaining sporadic cases with no family history. PubMed

17. Pathogenic variants clustered toward gene ends influencing phenotype through nonsense-mediated decay escape or protein truncation of regulatory domains. Zebrakinder

18. Chromatin-machinery disease mechanism—KAT6A belongs to epigenetic “writers”; its disruption broadly deranges developmental gene networks. BioMed Central

19. Potential second-hit/complex genetics (rare individuals may carry additional variants that modify severity), noted in cohort heterogeneity. PubMed

20. Inherited missense variants with variable expressivity, where a mildly affected parent has a child with clearer features. ScienceDirect

Common symptoms and features

1. Global developmental delay—children reach sitting, walking, and other milestones later than peers. National Organization for Rare Disorders+1

2. Intellectual disability—learning is harder; severity ranges from mild to moderate (occasionally more pronounced). orpha.net+1

3. Speech and language delay—first words and phrases arrive late; some children use few words and rely on therapy/augmentative communication. National Organization for Rare Disorders

4. Feeding difficulties in infancy—poor suck, reflux, or need for thickened feeds or tube feeding in severe cases. PubMed

5. Gastroesophageal reflux—stomach acid backing up into the esophagus, causing irritability or poor weight gain. Wikipedia

6. Chronic constipation—slow gut motility requiring diet changes or medications. Wikipedia

7. Congenital heart defects—commonly atrial or ventricular septal defects; sometimes patent ductus arteriosus/foramen ovale. Wikipedia+1

8. Low muscle tone (hypotonia)—“floppy” feel in infancy that improves with therapy. malacards.org

9. Distinctive facial features—often a broad nasal tip and thin, tented upper lip; some have microcephaly (small head size). orpha.net+1

10. Eye findings—strabismus (misalignment), amblyopia, or refractive errors needing glasses. Wikipedia

11. Sleep disturbances—difficulty falling or staying asleep. Wikipedia

12. Autism spectrum traits or social-communication differences—reported in a subset. Wikipedia

13. Seizures (epilepsy)—occasional; not universal. Wikipedia

14. Frequent infections—recurrent viral illnesses noted in reports. Wikipedia

15. Poor growth/feeding-related failure to thrive—especially in infancy, linked to reflux/feeding issues. PubMed

Diagnostic tests

Physical examination (bedside/clinic)

1. Detailed dysmorphology exam. A genetics-trained clinician looks for facial patterns (broad nasal tip, thin upper lip), head size, palate shape, limb tone, and other clues that suggest KAT6A syndrome and guide testing. orpha.net+1

2. Growth and nutrition assessment. Tracking weight, length/height, and head circumference helps flag feeding problems or microcephaly and prompts early interventions. PubMed

3. Cardiac auscultation and newborn/child heart screening. Murmurs or low oxygen can hint at septal defects that need imaging. Wikipedia

4. Developmental screening tools in clinic. Simple questionnaires and observation check language, motor, and social milestones to decide who needs formal evaluations. National Organization for Rare Disorders

Manual/functional assessments

1. Comprehensive speech-language evaluation. A speech-language pathologist measures receptive/expressive language and plans therapy or augmentative communication. National Organization for Rare Disorders
2. Feeding and swallowing study (clinical). A therapist evaluates suck, chew, and swallow coordination; results steer diet changes or thickened liquids. PubMed
3. Occupational/physical therapy evaluations. These hands-on tests score tone, posture, and fine/gross motor skills to build therapy plans. National Organization for Rare Disorders
4. Educational/behavioral assessments. Psychologists and educators test learning strengths/needs and autism traits to tailor school supports. BioMed Central

Laboratory / pathological genetics

1. Chromosomal microarray (CMA). Looks for missing or extra DNA segments that could include KAT6A or other genes; useful first-line in developmental delay. (A standard first-line test in neurodevelopmental disorders.) PubMed
2. Clinical exome or genome sequencing. The most direct way to find KAT6A variants causing this syndrome; detects single-letter changes and small insertions/deletions. PubMed+1
3. Targeted KAT6A sequencing (and Sanger confirmation). Used to confirm a suspected or inherited variant and to test parents or siblings. PubMed
4. Splice analysis (RNA studies) when needed. If a variant might affect splicing, RNA testing clarifies its impact on the message made from the gene. PubMed
5. Methylation/epigenetic signatures (research/selected labs). Some chromatin disorders show characteristic DNA-methylation patterns that support diagnosis; utility continues to evolve. BioMed Central

Electrodiagnostic / sensory tests

1. Electroencephalogram (EEG). If seizures are suspected, EEG records brain waves to confirm epilepsy and guide treatment. (Seizures occur in a subset.) Wikipedia
2. Auditory brainstem response (ABR) or formal hearing tests. Checks for hearing loss that might worsen speech delay. (Hearing assessment is routine in developmental syndromes.) PubMed
3. Polysomnography (sleep study) if needed. Evaluates insomnia or suspected sleep-disordered breathing that may worsen daytime behavior. Wikipedia

Imaging / specialist examinations

1. Echocardiogram (heart ultrasound). Detects atrial/ventricular septal defects or patent ductus arteriosus that may need monitoring or surgery. Wikipedia
2. Brain MRI (when indicated). Looks for structural differences or causes of seizures/developmental delay; helpful if neurological red flags arise. PubMed
3. Ophthalmology exam (including refraction and strabismus check). Identifies vision problems early to prevent amblyopia. Wikipedia
4. Gastroenterology evaluation ± swallow study imaging (videofluoroscopy). If reflux/aspiration is significant, imaging can show how safely the child swallows different textures. PubMed

Non-pharmacological treatments (therapies & others)

1. Early Intervention & Individualized Education (IEP/IFSP).
   A structured plan that starts as early as possible to support learning, movement, communication, and self-care. Purpose: improve developmental skills and school readiness. Mechanism: repeated guided practice builds brain pathways for language, cognition, and motor skills; classroom accommodations reduce learning barriers. rarediseases.info.nih.gov

2. Speech-Language Therapy (including augmentative communication).
   Therapy targets expressive language, understanding words, oral-motor skills, and safe swallowing. Devices or picture systems can help if speech is limited. Purpose: improve communication, reduce frustration, and support safe feeding. Mechanism: structured language exposure and muscle practice strengthen neural circuits for speech and language. National Organization for Rare Disorders

3. Feeding Therapy & Nutritional Support.
   Therapists teach safe chewing and swallowing; dietitians plan high-calorie options and texture changes. Purpose: improve growth and reduce aspiration. Mechanism: graded sensory-motor training and consistent practice adapt oral-motor patterns; nutrition meets energy needs for brain and body growth. National Organization for Rare Disorders

4. Physical Therapy.
   Exercises for posture, balance, and mobility; uses play-based motor tasks. Purpose: improve strength, endurance, and gross-motor milestones (sitting, standing, walking). Mechanism: repetition reshapes motor pathways and strengthens muscles, improving coordination. rarediseases.info.nih.gov

5. Occupational Therapy.
   Focus on hand use, daily living skills (feeding, dressing), sensory processing. Purpose: greater independence in home and school tasks. Mechanism: task-specific training promotes fine-motor control and adaptive behaviors. rarediseases.info.nih.gov

6. Behavioral Therapy (including parent-training).
   Teaches positive behavior strategies, routines, and reinforcement to handle attention, sleep, and feeding behaviors. Purpose: reduce challenging behaviors and improve learning time. Mechanism: behavior shaping using consistent cues and rewards builds desired habits. rarediseases.info.nih.gov

7. Vision Care & Strabismus Management (patching/orthoptics).
   Regular eye exams, glasses for refractive errors, and patching or exercises for strabismus/amblyopia. Purpose: protect and optimize vision for learning. Mechanism: correcting focus and strengthening weaker eye improves visual development. National Organization for Rare Disorders

8. Cardiology Monitoring & Activity Planning.
   Echocardiograms, rhythm checks, and safe activity guidance for heart defects or repairs. Purpose: prevent complications, support safe participation in play and school. Mechanism: surveillance detects treatable problems early; activity modifications lower strain on the heart. orpha.net

9. Sleep Hygiene Program.
   Consistent schedules, light control, bedtime routines, and screen limits. Purpose: better sleep quantity and quality. Mechanism: stable cues align the body clock and improve melatonin rhythms. rarediseases.info.nih.gov

10. Communication-Rich Home Environment.
    Caregivers use simple language, gestures, and high-frequency reading/talking. Purpose: accelerate language learning. Mechanism: more input increases language mapping in the brain. National Organization for Rare Disorders

11. Feeding Positioning & Thickened Liquids (when advised).
    Upright posture, pacing, and texture changes reduce choking and reflux. Purpose: safer feeding, fewer respiratory events. Mechanism: gravity and slower flow reduce aspiration risk. National Organization for Rare Disorders

12. Orthotics & Adaptive Equipment.
    Ankle-foot orthoses, supportive seating, or mobility aids. Purpose: stability for standing/walking and safe positioning. Mechanism: external support improves biomechanics and endurance. rarediseases.info.nih.gov

13. Craniofacial & Dental Care.
    Regular dental care; craniofacial team input for facial or palate issues. Purpose: improved feeding, speech, and oral health. Mechanism: structural support and dental hygiene reduce caries and improve articulation. orpha.net

14. Care Coordination & Social Work Support.
    Helps families access therapies, equipment, schooling, and benefits. Purpose: reduce care burden; maintain consistent follow-up. Mechanism: organized services prevent gaps in treatment. rarediseases.info.nih.gov

15. Physiatry (Rehabilitation Medicine).
    Guides spasticity/tone management, therapy intensity, and equipment prescriptions. Purpose: smooth long-term function and participation. Mechanism: periodic assessments fine-tune interventions for best outcomes. rarediseases.info.nih.gov

16. Regular Hearing Screening.
    Audiology checks for conductive or sensorineural loss. Purpose: ensure hearing supports speech development. Mechanism: early detection allows amplification or therapy to prevent language delays. rarediseases.info.nih.gov

17. Gastroenterology Care for Reflux/Constipation.
    Diet, routines, and toilet training; medical therapy if needed. Purpose: reduce pain and improve appetite and growth. Mechanism: consistent bowel routines and tailored diets support gut motility. National Organization for Rare Disorders

18. Immunization & Infection Prevention.
    Up-to-date vaccines and prompt care for infections. Purpose: protect vulnerable children from preventable illness. Mechanism: vaccines prime the immune system to fight specific pathogens. rarediseases.info.nih.gov

19. Genetic Counseling for Family Planning.
    Explains inheritance, recurrence risk, and testing options for relatives and future pregnancies. Purpose: informed choices for families. Mechanism: risk assessment based on autosomal-dominant transmission and de novo rates. rarediseases.info.nih.gov

20. Caregiver Training & Mental Health Support.
    Coaching in daily care, stress management, and access to support groups. Purpose: sustain family well-being and consistent caregiving. Mechanism: education and psychosocial support lower burnout and improve adherence. rarediseases.info.nih.gov

Drug treatments

Reality check first: There is no FDA-approved drug that treats the genetic cause of this syndrome. Medicines are used to treat specific symptoms (for example, seizures, reflux, constipation, attention, sleep, spasticity, or heart failure). Always use medicines only when clinically indicated by your doctor. Labels below come from accessdata.fda.gov. rarediseases.info.nih.gov

1. Levetiracetam (for seizures). Class: antiepileptic. Typical pediatric dosing is individualized; common oral ranges ~20–60 mg/kg/day in divided doses. Purpose: reduce seizure frequency. Mechanism: binds SV2A to modulate neurotransmitter release; good tolerability profile. Side effects: somnolence, irritability, behavioral changes; adjust in renal impairment. FDA Access Data+1

2. Lamotrigine (for seizures ± mood stabilization). Class: antiepileptic. Dosing is titrated slowly to reduce rash risk; pediatric doses vary by regimen and co-medications. Purpose: control focal/generalized seizures. Mechanism: inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating glutamate release. Side effects: serious rash (SJS/TEN) boxed warning, dizziness, headache; interactions with valproate. FDA Access Data

3. Valproic acid (Depakene) (for generalized or focal seizures; sometimes for mood). Class: antiepileptic. Dosing individualized; monitor liver function and ammonia; avoid in certain mitochondrial disorders and during pregnancy due to teratogenicity. Purpose: broad seizure control. Mechanism: increases GABA levels and modifies sodium/calcium channels. Side effects: boxed warnings for hepatotoxicity, pancreatitis, and teratogenicity; weight gain, tremor. FDA Access Data

4. Baclofen (for troublesome spasticity or high tone). Class: antispasticity agent. Oral doses are titrated; do not stop suddenly. Purpose: ease stiffness, improve comfort and care. Mechanism: GABA-B receptor agonist reduces excitatory neurotransmission to muscles. Side effects: sedation, dizziness; abrupt withdrawal can cause serious reactions. FDA Access Data+1

5. Intrathecal baclofen (for severe spasticity when oral therapy fails). Class: antispasticity via pump. Dose delivered by implanted pump; managed by specialists. Purpose: strong tone reduction with lower systemic effects. Mechanism: continuous GABA-B agonism in spinal cord. Side effects: pump complications; withdrawal is dangerous. FDA Access Data

6. Methylphenidate (Ritalin) (for ADHD symptoms impacting learning/therapy). Class: stimulant. Dosing individualized; start low and adjust. Purpose: improve attention and reduce hyperactivity/impulsivity. Mechanism: blocks dopamine and norepinephrine reuptake. Side effects: decreased appetite, insomnia, increased heart rate/BP; misuse risk. FDA Access Data

7. Atomoxetine (Strattera) (non-stimulant for ADHD). Class: selective norepinephrine reuptake inhibitor. Weight-based dosing; monitor mood. Purpose: attention improvement when stimulants are not suitable. Mechanism: increases synaptic norepinephrine. Side effects: GI upset, sleep changes; warning for suicidal ideation in children/adolescents. FDA Access Data

8. Guanfacine ER (Intuniv) (ADHD/impulsivity, tics, or sleep onset). Class: alpha-2A adrenergic agonist. 1–4 mg once daily; monitor BP/HR. Purpose: reduce hyperactivity/impulsivity and improve sleep initiation. Mechanism: reduces sympathetic outflow in prefrontal circuits. Side effects: sedation, hypotension, bradycardia. FDA Access Data+1

9. Clonidine ER (Kapvay) (ADHD or sleep-onset problems). Class: alpha-2 adrenergic agonist. Titrate slowly; do not stop abruptly. Purpose: calm behavior and aid sleep. Mechanism: central alpha-2 agonism reduces noradrenergic tone. Side effects: drowsiness, low BP, rebound hypertension if stopped suddenly. FDA Access Data

10. Omeprazole (Prilosec) (for significant GERD). Class: proton pump inhibitor. Typical pediatric dosing and duration per label; timing before meals. Purpose: reduce acid and pain from reflux; protect esophagus. Mechanism: blocks gastric H+/K+ ATPase, lowering acid secretion. Side effects: headache, abdominal pain; long-term risks include low magnesium and infections. FDA Access Data

11. Lansoprazole (Prevacid) (GERD/erosive esophagitis). Class: proton pump inhibitor. Dosing varies by age/indication; do not use longer than needed. Purpose: symptom relief and healing of esophagitis. Mechanism: PPI acid suppression. Side effects: similar to omeprazole. FDA Access Data

12. Metoclopramide (Reglan) (selected cases of refractory reflux with delayed gastric emptying—specialist use). Class: prokinetic/antiemetic. Short-term use only; significant safety warnings. Purpose: improve gastric emptying and reduce vomiting. Mechanism: dopamine-2 antagonism and 5-HT4 agonism enhance GI motility. Side effects: boxed warning for tardive dyskinesia, sedation, dystonia—use cautiously. FDA Access Data

13. Polyethylene glycol 3350 (MiraLAX) (for constipation). Class: osmotic laxative. Dosing per label; mix in liquid. Purpose: soften stool and ease passage. Mechanism: holds water in the stool, increasing stool volume and motility. Side effects: bloating, cramping; ensure adequate fluids. FDA Access Data

14. Lubiprostone (Amitiza) (older children/adults with chronic idiopathic constipation; specialist guidance). Class: chloride channel activator. Capsules with meals and water. Purpose: improve stool frequency and ease. Mechanism: activates ClC-2 channels to increase intestinal fluid and motility. Side effects: nausea, diarrhea; avoid if GI obstruction. FDA Access Data

15. Linaclotide (Linzess) (constipation/IBS-C in appropriate ages). Class: GC-C agonist. Take on empty stomach; avoid in children under 2 due to dehydration risk. Purpose: reduce constipation and abdominal pain in IBS-C. Mechanism: increases intestinal chloride and fluid, speeds transit. Side effects: diarrhea, abdominal pain. FDA Access Data

16. Furosemide (Lasix) (for heart-failure symptoms in significant cardiac defects before/after surgery, when indicated by cardiology). Class: loop diuretic. Careful dosing and monitoring. Purpose: reduce fluid overload and ease breathing. Mechanism: inhibits Na-K-2Cl transporter in the loop of Henle to increase urine output. Side effects: electrolyte loss, dehydration, ototoxicity at high doses. FDA Access Data+1

17. Amoxicillin (for bacterial infections such as otitis media or pneumonia when diagnosed). Class: penicillin antibiotic. Weight-based dosing and duration per infection. Purpose: treat documented bacterial infections and reduce complications. Mechanism: inhibits bacterial cell-wall synthesis. Side effects: rash, diarrhea; allergy risk. FDA Access Data

18. Keppra XR (levetiracetam extended-release) (adolescent/adult once-daily option). Class: antiepileptic. Purpose/Mechanism/Side effects: same as levetiracetam; XR improves adherence with once-daily dosing. FDA Access Data

19. Lamotrigine XR (if extended-release is preferred, per neurology). Class: antiepileptic. Purpose/Mechanism/Side effects: same as lamotrigine; slow titration remains essential due to rash risk. FDA Access Data

20. Tasimelteon or Ramelteon (selected sleep-wake problems under specialist care). Class: melatonin receptor agonists. Purpose: help circadian rhythm-related sleep disturbance in neurodevelopmental disorders when appropriate. Mechanism: agonism at MT1/MT2 receptors stabilizes sleep cycle timing. Side effects: somnolence, abnormal dreams; use under guidance. FDA Access Data+1

Note: Drug choice and dosing must be individualized by a clinician, considering age, comorbidities, heart status, feeding/swallowing safety, and drug interactions. Labels above are for general reference to FDA-approved uses and safety information. They are not treatment prescriptions. FDA Access Data

Dietary molecular supplements

1. Omega-3 fatty acids (DHA/EPA). May support attention and behavior in some children and general heart health. Typical pediatric doses vary; many use 250–500 mg combined EPA+DHA daily (check with clinician). Function: membrane fluidity and anti-inflammatory signaling. Mechanism: incorporate into neuronal membranes; modulate eicosanoids. (General nutrition guidance; discuss with your clinician.) National Organization for Rare Disorders

2. Vitamin D (if low). Dose: per blood level and pediatric guidance. Function: bone health and immune function. Mechanism: nuclear receptor effects regulate calcium and immune pathways. (Use only if deficient.) rarediseases.info.nih.gov

3. Calcium (diet first; supplement if needed). Function: bone mineralization, muscle and nerve function. Mechanism: supports skeletal growth, especially important if limited weight-bearing. rarediseases.info.nih.gov

4. Iron (if iron-deficiency is proven). Dose: weight-based elemental iron under medical supervision. Function: hemoglobin and neurodevelopment. Mechanism: restores oxygen transport and enzymatic functions; improves fatigue. rarediseases.info.nih.gov

5. Multivitamin (age-appropriate). For children with restricted diets. Function: fills micronutrient gaps. Mechanism: provides daily recommended vitamins/minerals to support growth. rarediseases.info.nih.gov

6. Probiotics (selected strains). May reduce constipation or antibiotic-associated diarrhea for some children. Mechanism: modulate gut microbiota and SCFA production. Dose/strain vary; discuss with clinician. rarediseases.info.nih.gov

7. Fiber supplement (psyllium/inulin), if diet is low in fiber. Function: stool bulk and softer stools. Mechanism: increases stool water and promotes motility. Start low, increase slowly. rarediseases.info.nih.gov

8. Magnesium citrate or oxide (constipation), if advised. Function: osmotic laxative effect. Mechanism: draws water into intestine; can help stooling. Use with guidance. rarediseases.info.nih.gov

9. Coenzyme Q10 (select fatigue cases under specialist care). Function: mitochondrial electron transport. Mechanism: supports oxidative phosphorylation; evidence in syndromic ID is limited. rarediseases.info.nih.gov

10. Protein/calorie supplements (for poor weight gain). Function: adequate calories and protein for growth. Mechanism: supports tissue building and immune function when oral intake is low. National Organization for Rare Disorders

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved “stem-cell” or “regenerative” drugs specifically for this syndrome. Stem-cell products outside approved indications can be unsafe. Management should focus on vaccines, nutrition, physical therapies, and treating complications; investigational therapies belong in IRB-approved clinical trials only. rarediseases.info.nih.gov

If clinicians identify clear, approved medical indications (e.g., spasticity, seizures, reflux), they may use approved drugs listed above for those indications. Using unapproved “immune boosters” is not advised without evidence and medical supervision. rarediseases.info.nih.gov

Surgeries

1. Surgical repair of congenital heart defects (e.g., ASD/VSD/PDA). Why: prevent heart failure, pulmonary hypertension, and improve growth and energy. Timing and technique depend on defect size and symptoms. orpha.net

2. Gastrostomy tube (G-tube) for severe feeding/swallowing problems. Why: secure nutrition, reduce aspiration risk, and support safe medication delivery if oral intake is unsafe. National Organization for Rare Disorders

3. Strabismus surgery for significant eye misalignment not corrected with glasses/patching. Why: improve alignment, binocular vision, and reduce amblyopia risk. National Organization for Rare Disorders

4. Craniofacial procedures (selected cases, e.g., craniosynostosis or palate issues). Why: protect brain growth, improve airway/feeding, and support speech development. orpha.net

5. ENT procedures (e.g., tympanostomy tubes, tonsil/adenoid surgery when indicated). Why: reduce ear infections, improve hearing, or treat sleep-disordered breathing to support development. rarediseases.info.nih.gov

Preventions

1. Genetic counseling to discuss inheritance and recurrence risk. rarediseases.info.nih.gov

2. Prenatal and preimplantation options for future pregnancies when a familial variant is known. rarediseases.info.nih.gov

3. Routine vaccinations and infection prevention strategies. rarediseases.info.nih.gov

4. Early therapy enrollment to prevent secondary delays. rarediseases.info.nih.gov

5. Regular cardiac follow-up to prevent late complications. orpha.net

6. Eye and hearing screening to catch problems early. National Organization for Rare Disorders

7. Safe feeding plans to prevent aspiration and poor growth. National Organization for Rare Disorders

8. Dental care and fluoride to prevent caries and pain. orpha.net

9. Sleep hygiene to prevent behavior and learning setbacks from poor sleep. rarediseases.info.nih.gov

10. Care coordination to prevent missed services and therapy gaps. rarediseases.info.nih.gov

When to see doctors (red flags)

See your clinician urgently for breathing trouble, blue lips/skin, poor feeding, repeated vomiting, dehydration, fever with lethargy, new or worsening seizures, or any sign of heart failure (rapid breathing, sweating with feeds, poor weight gain). Also arrange prompt review for strabismus/vision loss, regression in skills, severe constipation with abdominal swelling, or unexplained behavior changes. Regularly scheduled visits with cardiology, genetics, neurology, gastroenterology, ophthalmology, and developmental specialists are important even when your child seems “well.” orpha.net+1

What to eat and what to avoid

What to eat: balanced diet rich in fruit, vegetables, whole grains, lean protein, healthy fats, and adequate calories for growth; fiber and water to help constipation; fortified foods and dairy/alternatives for calcium and vitamin D when appropriate. Tailor textures for safe swallowing (purees/soft foods) if advised by feeding therapy. National Organization for Rare Disorders

What to avoid: foods that are choking risks (hard nuts, hard candy) if oral-motor skills are delayed; heavy, spicy, or acidic meals near bedtime if reflux is an issue; excessive juice/sugary drinks that worsen diarrhea; and any supplements not reviewed by your clinician. If your child has a tube-feeding plan, follow the formula and schedule exactly as provided. National Organization for Rare Disorders

Frequently asked questions

1. Is this syndrome the same as KAT6A syndrome?
   Yes. “Autosomal dominant intellectual disability–craniofacial anomalies–cardiac defects syndrome” is also called Arboleda-Tham (KAT6A) syndrome. rarediseases.info.nih.gov+1

2. What causes it?
   A pathogenic variant in the KAT6A gene in most cases; usually de novo, sometimes inherited. orpha.net

3. How common is it?
   Very rare. Only a small number of people are reported worldwide. rarediseases.info.nih.gov

4. What are the main features?
   Developmental delay, speech delay, distinctive facial features, and congenital heart defects; feeding and eye problems are common. orpha.net+1

5. How is it diagnosed?
   By genetic testing that finds a KAT6A variant. orpha.net

6. Can it be cured?
   There is no cure yet; care is supportive and individualized. rarediseases.info.nih.gov

7. Will my child walk and talk?
   Many do, but timelines vary; early therapies help maximize skills. National Organization for Rare Disorders

8. Are heart surgeries always needed?
   Not always; it depends on the type and size of the defect and symptoms. Cardiology decides the timing. orpha.net

9. Are seizures expected?
   Some children have seizures; if present, neurology may use antiepileptic medicines such as levetiracetam or lamotrigine. FDA Access Data+1

10. What about constipation and reflux?
    Common and treatable with diet, schedules, and medicines like PEG 3350, lubiprostone, linaclotide, or PPIs when indicated. FDA Access Data+3FDA Access Data+3FDA Access Data+3

11. Do ADHD medicines help?
    If ADHD-like symptoms cause impairment, clinicians may use stimulants or non-stimulants such as atomoxetine or guanfacine/clonidine. FDA Access Data+3FDA Access Data+3FDA Access Data+3

12. Is melatonin safe to use?
    Some children use melatonin receptor agonists (ramelteon/tasimelteon) under specialist care; always discuss risks and benefits. FDA Access Data+1

13. Are “stem-cell therapies” recommended?
    No—there are no approved stem-cell drugs for this condition; consider only clinical trials and avoid unregulated products. rarediseases.info.nih.gov

14. What screenings are needed?
    Regular cardiac, vision, hearing, growth, and developmental checks; GI follow-up if feeding or constipation is present. orpha.net+1

15. Where can I read more?
    See GARD, Orphanet, NORD, and curated genetics resources linked below. rarediseases.info.nih.gov+2orpha.net+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 02, 2025.